Troy Edward Wilson
CIK: 0001589597
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (31 total)
- Sep 14, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct5K shares at avg. $9.10$46K - Aug 24, 2026KURA
Kura Oncology, Inc.
Purchase(P)Indirect100K shares at avg. $12.39$1.2M - Aug 17, 2026KURA
Kura Oncology, Inc.
Purchase(P)Indirect100K shares at avg. $11.12$1.1M - Jun 12, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct10.8K shares at avg. $7.20$78K - Jun 11, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Award(A)Direct27K shares- - Mar 23, 2026KURA
Kura Oncology, Inc.
Exercise(M)Direct6.1K shares at avg. $6.15$38K - Feb 27, 2026RNA
Atrium Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Indirect13.7K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Direct65.1K shares- - Jan 2, 2026KURA
Kura Oncology, Inc.
Award(A)DirectOption to purchase common stock
1.1M shares- - Nov 13, 2025KURA
Kura Oncology, Inc.
Award(A)Direct182.5K shares- - Sep 29, 2025KURA
Kura Oncology, Inc.
Sale(S)Direct36.6K shares at avg. $8.94$327K - Sep 27, 2025KURA
Kura Oncology, Inc.
Award(A)Direct182.5K shares- - Sep 8, 2025KURA
Kura Oncology, Inc.
Purchase(P)Direct50K shares at avg. $8.20$410K - Sep 5, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct14.5K shares at avg. $12.48$181K - Sep 5, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct14.5K shares at avg. $50.00$725K - Sep 5, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct15K shares at avg. $50.00$750K - Aug 13, 2025KURA
Kura Oncology, Inc.
Purchase(P)Direct13.5K shares at avg. $6.64$90K - Aug 12, 2025KURA
Kura Oncology, Inc.
Purchase(P)Direct36.5K shares at avg. $5.85$214K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Indirect17.8K shares at avg. $45.00$800K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Indirect15K shares at avg. $45.00$675K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Indirect15K shares at avg. $45.00$675K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct7.5K shares at avg. $45.00$338K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct7.5K shares at avg. $12.48$94K - Aug 6, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct22K shares at avg. $12.03$265K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 5,000 | $9.10 | $45,500 | Direct |
| Aug 24, 2026 |  KURA Kura Oncology, Inc. | Purchase(P) | 100,000 | $12.39 | $1,239,000 | Indirect |
| Aug 17, 2026 | KURA Kura Oncology, Inc. | Purchase(P) | 100,000 | $11.12 | $1,112,000 | Indirect |
| Jun 12, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 10,800 | $7.20 | $77,748 | Direct |
| Jun 11, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | Award(A) | 27,000 | - | $0 | Direct |
| Mar 23, 2026 | KURA Kura Oncology, Inc. | Exercise(M) | 6,103 | $6.15 | $37,533 | Direct |
| Feb 27, 2026 |  RNA Atrium Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition(D) | 13,711 | - | $0 | Indirect |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc. | Disposition(D) | 65,091 | - | $0 | Direct |
| Jan 2, 2026 | KURA Kura Oncology, Inc. | Award(A) Option to purchase common stock | 1,120,000 | - | - | Direct |
| Nov 13, 2025 | KURA Kura Oncology, Inc. | Award(A) | 182,500 | - | - | Direct |
| Sep 29, 2025 | KURA Kura Oncology, Inc. | Sale(S) | 36,615 | $8.94 | $327,419 | Direct |
| Sep 27, 2025 | KURA Kura Oncology, Inc. | Award(A) | 182,500 | - | - | Direct |
| Sep 8, 2025 | KURA Kura Oncology, Inc. | Purchase(P) | 50,000 | $8.20 | $410,145 | Direct |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 14,500 | $12.48 | $180,960 | Direct |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 14,500 | $50.00 | $725,000 | Direct |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 15,000 | $50.00 | $750,000 | Direct |
| Aug 13, 2025 | KURA Kura Oncology, Inc. | Purchase(P) | 13,494 | $6.64 | $89,623 | Direct |
| Aug 12, 2025 | KURA Kura Oncology, Inc. | Purchase(P) | 36,506 | $5.85 | $213,578 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 17,777 | $45.00 | $799,965 | Indirect |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 15,000 | $45.00 | $675,000 | Indirect |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 15,000 | $45.00 | $675,000 | Indirect |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 7,500 | $45.00 | $337,500 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 7,500 | $12.48 | $93,600 | Direct |
| Aug 6, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 22,000 | $12.03 | $264,660 | Direct |
1-25 of 31 transactions
About WILSON TROY EDWARD
WILSON TROY EDWARD (SEC CIK 0001589597) files insider reports with the SEC as Director of PUMA BIOTECHNOLOGY, INC. (PBYI), President and CEO of Kura Oncology, Inc. (KURA) and Director of Atrium Therapeutics, Inc. (RNA). Signal8 also holds filings tied to 1 other company.
Signal8 holds 19 ownership filings by WILSON TROY EDWARD (1 Form 3, 18 Form 4), filed between Jan 6, 2025 and Sep 16, 2026. Those filings report 31 transactions, from Jan 2, 2025 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WILSON TROY EDWARD's filings is in LOS ANGELES, CA.
Recent filings by WILSON TROY EDWARD
- Sep 14, 2026: Open-market sale of PBYI shares (Form 4, code S).
- Aug 24, 2026: Open-market purchase of KURA shares (Form 4, code P).
- Aug 17, 2026: Open-market purchase of KURA shares (Form 4, code P).
- Jun 12, 2026: Open-market sale of PBYI shares (Form 4, code S).
- Jun 11, 2026: Grant or award of PBYI shares (Form 4, code A).
Other insiders filing for PUMA BIOTECHNOLOGY, INC. (PBYI)
- Cesano Alessandra, Director
- AUERBACH ALAN H, President and CEO
- HUNT DOUGLAS M
- NOUGUES MAXIMO F, Chief Financial Officer
- Stuglik Brian M, Director
- Senderowicz Adrian, Director